Royal Bank of Canada Has $23.96 Million Stock Position in Omnicell, Inc. $OMCL

Royal Bank of Canada trimmed its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 3.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 685,206 shares of the company's stock after selling 26,972 shares during the period. Royal Bank of Canada owned approximately 1.46% of Omnicell worth $23,955,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Diversified Trust Co grew its position in shares of Omnicell by 2.3% during the first quarter. Diversified Trust Co now owns 22,660 shares of the company's stock worth $792,000 after purchasing an additional 513 shares in the last quarter. Bridge City Capital LLC increased its holdings in shares of Omnicell by 1.6% in the 1st quarter. Bridge City Capital LLC now owns 40,136 shares of the company's stock valued at $1,403,000 after acquiring an additional 650 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Omnicell by 4.6% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 15,832 shares of the company's stock valued at $553,000 after acquiring an additional 696 shares during the period. EntryPoint Capital LLC grew its stake in Omnicell by 21.6% during the 1st quarter. EntryPoint Capital LLC now owns 6,671 shares of the company's stock worth $233,000 after buying an additional 1,184 shares during the last quarter. Finally, Wakefield Asset Management LLLP lifted its position in Omnicell by 8.1% during the 1st quarter. Wakefield Asset Management LLLP now owns 25,517 shares of the company's stock worth $892,000 after acquiring an additional 1,906 shares during the period. Hedge funds and other institutional investors own 97.70% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on OMCL shares. Piper Sandler decreased their price target on Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 11th. Wells Fargo & Company lifted their price objective on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a report on Monday, July 21st. Wall Street Zen downgraded shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Bank of America boosted their price target on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Price Performance

NASDAQ:OMCL traded down $0.91 during trading hours on Wednesday, reaching $31.86. 512,120 shares of the company's stock were exchanged, compared to its average volume of 509,246. The business's 50-day simple moving average is $30.59 and its two-hundred day simple moving average is $31.21. The company has a market capitalization of $1.46 billion, a P/E ratio of 63.72, a price-to-earnings-growth ratio of 7.16 and a beta of 0.82. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.74. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm had revenue of $290.56 million during the quarter, compared to analyst estimates of $275.57 million. During the same quarter in the previous year, the business earned $0.51 EPS. The business's revenue was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Sell-side analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.